Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial
University Hospital of Lausanne · University Hospital of Zurich · +35 more institutions
Indexed incrossrefdatacitepubmed
Abstract
No abstract available for this paper.
Citation impact
1,016
total citations
- FWCI
- 54.30
- Percentile
- 100%
- References
- 36
Citations per year
Authors
37- RSRoger StuppCorresponding
University Hospital of Lausanne, University Hospital of Zurich, University of Lausanne
- MEMonika E. Hegi
University Hospital of Lausanne, University of Lausanne
- TGThierry Gorlia
European Organisation for Research and Treatment of Cancer
- SESara Erridge
Edinburgh Cancer Research
- JPJames Perry
Sunnybrook Health Science Centre, Health Sciences Centre
Topics & keywords
Topics
Keywords
- Temozolomide
- Medicine
- Chemoradiotherapy
- Internal medicine
- Oncology
- Clinical endpoint
- Phases of clinical research
- Progression-free survival
No related works found for this paper.